J.P. Maroto Rey

476 total citations
15 papers, 116 citations indexed

About

J.P. Maroto Rey is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, J.P. Maroto Rey has authored 15 papers receiving a total of 116 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 5 papers in Surgery. Recurrent topics in J.P. Maroto Rey's work include Prostate Cancer Treatment and Research (6 papers), Renal cell carcinoma treatment (5 papers) and Bladder and Urothelial Cancer Treatments (4 papers). J.P. Maroto Rey is often cited by papers focused on Prostate Cancer Treatment and Research (6 papers), Renal cell carcinoma treatment (5 papers) and Bladder and Urothelial Cancer Treatments (4 papers). J.P. Maroto Rey collaborates with scholars based in Spain, France and United Kingdom. J.P. Maroto Rey's co-authors include Sergio Bracarda, Yao Yu, Jonathan E. Rosenberg, Peter H. O’Donnell, Helen Moon, Terence W. Friedlander, Daniel P. Petrylak, Begoña P. Valderrama, Earle F. Burgess and Emilio Esteban and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Critical Reviews in Oncology/Hematology.

In The Last Decade

J.P. Maroto Rey

15 papers receiving 116 citations

Peers

Countries citing papers authored by J.P. Maroto Rey

Since Specialization

Citations

This map shows the geographic impact of J.P. Maroto Rey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.P. Maroto Rey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.P. Maroto Rey more than expected).

Fields of papers citing papers by J.P. Maroto Rey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.P. Maroto Rey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.P. Maroto Rey. The network helps show where J.P. Maroto Rey may publish in the future.

Co-authorship network of co-authors of J.P. Maroto Rey

This figure shows the co-authorship network connecting the top 25 collaborators of J.P. Maroto Rey. A scholar is included among the top collaborators of J.P. Maroto Rey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.P. Maroto Rey. J.P. Maroto Rey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	1966MO EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC) 2024 ·Annals of Oncology ·Thomas Powles, Michiel S. van der Heijden, Shilpa Gupta, Begoña P. Valderrama, (unknown), (unknown), Eiji Kikuchi, Jean Hoffman‐Censits, J.P. Maroto Rey, Christof Vulsteke, Gopa Iyer, Umang Swami, Sang Joon Shin, Alejo Rodríguez‐Vida, Michał Woźniak, Blanca Homet Moreno, Jie Lu, Changjun Yu, Leah J. Hogdal, Yohann Loriot	13
2	1654P TAMARACK: Randomized Phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC) 2024 ·Annals of Oncology ·(unknown), Carole Hélissey, (unknown), J.P. Maroto Rey, Guilhem Roubaud, Emmanuel S. Antonarakis, Shahneen Sandhu, (unknown), (unknown), Begoña P. Valderrama, Christof Vulsteke, (unknown), (unknown), Eric Y. Stutheit-Zhao, Alex Ward, J.M. Piulats Rodriguez	7
3	LBA75 Prospective randomised phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer: Results of the SUNNIFORECAST trial 2024 ·Annals of Oncology ·Lars Bergmann, Marit Ahrens, (unknown), M. Gross Goupil, Ekaterini Boleti, Gwénaëlle Gravis, (unknown), (unknown), (unknown), (unknown), (unknown), B. Mellado González, (unknown), (unknown), (unknown), J.P. Maroto Rey, (unknown), Iris Burkholder, A. Hartmann, John B.A.G. Haanen	14
4	1883MO MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC) 2023 ·Annals of Oncology ·Martin H. Voss, Benjamin Garmezy, (unknown), J.P. Maroto Rey, André Mansinho, Alejo Rodríguez‐Vida, Júlio Oliveira, Martien van Dongen, (unknown), Sylvie Négrier, Ben Tran, Benedito A. Carneiro, (unknown), Sun Young Rha, Yan Wang, Shelby D. Gainer, Zhiyuan Tang, Ikbel Achour, (unknown), Laurence Albigès	7
5	1450MO Efficacy of a tailored approach with nivolumab and nivolumab/ipilimumab as immunotherapeutic boost in metastatic renal cell carcinoma: Final results of TITAN-RCC 2022 ·Annals of Oncology ·Marc‐Oliver Grimm, Emilio Esteban, (unknown), (unknown), (unknown), Begoña P. Valderrama, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), J.P. Maroto Rey, Laurence Albigès	5
6	LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) 2022 ·Annals of Oncology ·Jonathan E. Rosenberg, (unknown), Chethan Ramamurthy, Nataliya Mar, Rana R. McKay, Terence W. Friedlander, (unknown), Sergio Bracarda, Saby George, Helen Moon, Daniel M. Geynisman, Daniel P. Petrylak, Delphine Borchiellini, Earle F. Burgess, J.P. Maroto Rey, (unknown), Yao Yu, (unknown), Blanca Homet Moreno, Peter H. O’Donnell	30
7	631P Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration resistant prostate cancer in an open-label phase Ib study 2021 ·Annals of Oncology ·Alejo Rodríguez‐Vida, J.P. Maroto Rey, Albert Font Pous, Cristina Martín, Begoña Mellado, (unknown), (unknown), Òscar Reig, (unknown), (unknown), (unknown), Jordi Alonso, (unknown), Núria Juanpere, Óscar Juan, Joaquim Bellmunt	1
8	695TiP ORACULUM: A retrospective observational epidemiological study using artificial intelligence and natural language processing in electronic health records to characterize the prostate cancer pathway, management and outcomes in Europe, Middle East and Africa (EMEA region) 2020 ·Annals of Oncology ·Joan Carles, Antonio Alcaraz, Noel W. Clarke, Antonio J. Conde-Moreno, Axel Heidenreich, (unknown), J.P. Maroto Rey, Javier Puente, Ignacio Hernández Medrano, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Karim Fizazi	2
9	Recent advances in genitourinary tumors: A review focused on biology and systemic treatment 2017 ·Critical Reviews in Oncology/Hematology ·Aranzazu González del Alba, José Ángel Arranz, Javier Puente, María José Méndez-Vidal, Enrique Gallardo, Enrique Grande, Begoña Pérez‐Valderrama, Enrique González‐Billalabeitia, Martín Lázaro-Quintela, Álvaro Pinto, Núria Laínez, Josep M. Piulats, Emilio Esteban, J.P. Maroto Rey, Jorge A. García, Cristina Suárez	15
10	SPAZO2 (SOGUG): Comparative effectiveness of pazopanib in metastatic renal carcinoma (mRC): Ineligible (I) vs eligible (E) patients for clinical trials 2017 ·Annals of Oncology ·(unknown), Begoña P. Valderrama, (unknown), Isabel Chirivella González, (unknown), J.P. Maroto Rey, (unknown), Miguel Á. Climent Durán, (unknown), Jorge A. García, Alejo Rodríguez‐Vida, Ricardo Fernández, Carmen Santander, (unknown), (unknown), (unknown), (unknown), (unknown), Sara Ramírez, (unknown)	2
11	Phase II study of pazopanib and weekly paclitaxel in metastatic or locally advanced squamous penile carcinoma patients previously treated with cisplatin-based chemotherapy: PAZOPEN study. 2015 ·Journal of Clinical Oncology ·Miguel Ángel Climent, Javier Puente, Sergio Vázquez‐Estévez, María José Méndez-Vidal, Enrique González‐Billalabeitia, Núria Laínez, J.P. Maroto Rey, Juan Francisco Rodríguez-Moreno, Xavier García del Muro	1
12	Prognostic significance of thromboembolic events in chemotherapy-treated germ cell tumors. 2015 ·Journal of Clinical Oncology ·Enrique González‐Billalabeitia, Josep Gumà, Daniel Castellano, (unknown), Jorge Aparicio, Alfonso Sánchez Muñoz, Begoña Mellado, A. Sáenz, Claudia Valverde, António Fernández, Mireia Margelí Vila, Ignacio Durán, (unknown), Javier Sastre, (unknown), J.P. Maroto Rey, Alberto Carmona‐Bayonas, Francisco Ayala, David Hervás, J. R. Germa-Lluch, (unknown)	1
13	Open-label, phase II raptor study of everolimus (EVE) for papillary mRCC: Efficacy in type 1 and type 2 histology. 2014 ·Journal of Clinical Oncology ·Bernard Escudier, Sergio Bracarda, J.P. Maroto Rey, Cezary Szczylik, Paul Nathan, Sylvie Négrier, Agnese Cattaneo, Claudia Weiß, Camillo Porta, Viktor Gruenwald	12
14	Impact of prior therapy with ketoconazol or abiraterone and pattern of PSA response in a cohort of patients with metastatic castrate resistant prostate cancer (mCRPC) receiving enzalutamide for postdocetaxel. 2014 ·Journal of Clinical Oncology ·J.P. Maroto Rey, Emilio Esteban, Alfonso Gómez de Liaño, (unknown), (unknown), E. Moreno	2
15	Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients 2009 ·Clinical & Translational Oncology ·Alfredo Carrato, Luis Paz‐Ares, Álvaro Rodríguez Lescure, (unknown), Eduardo Díaz‐Rubio, Pedro Pérez Segura, (unknown), Rocio García‐Carbonero, José Codina, Ana Lluch Hernández, J.P. Maroto Rey, M. Martín Jiménez, (unknown), (unknown), Antonio Rueda‐Domínguez	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact